David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)
October 23, 2024 07:27 AM EDTUpdated 11:09 AM
Pharma

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Kyle LaHucik

Senior Reporter

Eli Lil­ly’s Alzheimer’s drug Kisun­la is like­ly to face an up­hill up­take bat­tle in the UK af­ter its lo­cal cost-ef­fec­tive­ness watch­dog NICE

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times